Emergent BioSolutions Announces Presentation on Bispecific Protein Therapeutic at 24th Annual EORTC-NCI-AACR Symposium
The preclinical results showed Emergent’s SCORPIONTM (multi-specific protein therapeutic) molecules targeting prostate-specific membrane antigen (PSMA) and CD3 redirected T-cell cytotoxicity against PSMA-positive tumor cells and show potential for further investigation as possible therapeutic agents for treating castrate-resistant prostate cancer. T-cell engaging bispecific molecules linking anti-PSMA and anti-CD3 binding domains in the context of novel SCORPION proteins were evaluated both in vitro and in vivo for function and stability.
POSTER: Anti-Prostate Specific Membrane Antigen (PSMA) x anti-CD3 Bispecific Antibody Efficiently Redirects T Cell Cytotoxicity in Castrate-Resistant Prostate Cancer Models
|
Date: |
Thursday, November 8, 2012 |
|
|
Presentation Time: |
12:00 PM - 2:15 PM |
|
|
Location: |
Wicklow Hall, Convention Center Dublin |
|
About Prostate Cancer and Bispecific Therapies
Prostate cancer is the most common cancer in men. Although screening, radiation, surgery and hormone ablation therapy have greatly improved the detection and treatment of early stage prostate cancer, few options exist to treat metastatic, castrate-resistant prostate cancer. Bispecific antibody fragments that can simultaneously engage T cells and tumor cells have been shown to destroy tumor cells by redirecting the cytotoxic function of T cells.
About
Follow us on twitter: @emergentbiosolu.
Source:
Emergent BioSolutions Inc.
Investor Contact
Robert G.
Burrows, 301-795-1877
Vice President, Investor Relations
BurrowsR@ebsi.com
or
Media
Contact:
Tracey Schmitt, 301-795-1800
Vice President,
Corporate Communications
SchmittT@ebsi.com